Oncopeptides

Declaration of Voting Results & Voting Rights Announcements • Feb 28, 2025

Number of shares and votes in Oncopeptides

Stockholm — 28 February, 2025 — Oncopeptides AB (publ) (Nasdaq Stockholm: ONCO), a biotech company focused on difficult-to-treat cancers, today announces that the number of shares and votes in Oncopeptides has changed as a result of the company's issue of 10,572,577 new class C shares. The shares are issued by virtue of the Annual General Meetings' resolution on 31 May 2024 on authorisation for the Board of Directors to resolve on issue of class C shares to enable delivery of shares to participants under the incentive programs Co-worker LTIP 2022, Co-worker LTIP 2024 and Board SHP 2024 as well as other outstanding shareholder programs for members of the Board of Directors.

Before the share issue, the total number of shares in Oncopeptides amounted to 215,186,246 and the total number of votes in Oncopeptides amounted to 211,656,137.3. As a result of the share issue, the number of shares in Oncopeptides has increased by 10,572,577 class C shares, corresponding to 1,057,257.7 votes. As of today, the total number of shares in Oncopeptides amounts to 225,758,823 shares, of which 211,263,903 are ordinary shares and 14,494,920 are class C shares. The number of votes in Oncopeptides as of today amounts to 212,713,395. The share capital has increased by SEK 1,174,730.825486 from SEK 23,909,583.859895 to SEK 25,084,314.685381.

For more information, please contact:

David Augustsson, Director of IR and Communications, Oncopeptides AB (publ) E-mail: david.augustsson@oncopeptides.com Cell phone: +46 76 229 38 68

This information is information that Oncopeptides is obliged to make public pursuant to the Financial Instruments Trading Act. The information was submitted for publication at 2025-02-28 17:50 CET.

About Oncopeptides

Oncopeptides is a Swedish biotech company focusing on research, development and commercialization of targeted therapies for difficult-to-treat cancers.

The company uses its proprietary Peptide Drug Candidate platform (PDC) to develop compounds that rapidly and selectively deliver cytotoxic agents into cancer cells. Its flagship drug is currently being commercialized in Europe with partnership agreements for South Korea, the Middle East and Africa and elsewhere.

Oncopeptides is also developing several new compounds based on its two proprietary technology platforms PDC and SPiKE.

The company was founded in 2000, has about 80 employees with operations in Sweden, Germany, Austria, Spain and Italy. Oncopeptides is listed on Nasdaq Stockholm with the ticker ONCO.

For more information see: www.oncopeptides.com

Press Release 28 February 2025 17:50:00 CET

Attachments

Number of shares and votes in Oncopeptides